Actively Recruiting
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
Led by Shenyang Northern Hospital · Updated on 2025-09-10
3490
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese patients which has been demonstrated superior predictive capabilities for ischemic events and all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month, while high-risk patients could be de-escalated after 3 months, so as to achieve individualized antithrombotic therapy and maximize patient benefit.
CONDITIONS
Official Title
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 to 80 years
- Clinically diagnosed with acute coronary syndrome who have undergone at least one drug-eluting stent implantation
- Able to complete the OPT-CAD score calculation
- Able to tolerate at least 12 months of dual antiplatelet therapy
- Provided written informed consent
You will not qualify if you...
- Underwent PCI involving left main coronary artery lesion
- Allergic to aspirin, clopidogrel, or ticagrelor
- Meet 1 major or 2 minor criteria for high bleeding risk based on ARC-HBR criteria
- Expected to need revascularization or surgery within 12 months
- Experienced severe ischemia or hemorrhage during current hospitalization
- Have another serious disease with life expectancy under 1 year
- Pregnant or women planning to conceive within 1 year
- Currently participating in other clinical trials
- Considered ineligible by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110016
Actively Recruiting
Research Team
Y
Yi Li, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here